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Cancer mortality rates and trends over the period 1980–2000 for accession countries to the
European Union (EU) in May 2004, which include a total of 75 million inhabitants, were abstracted
from the World Health Organization (WHO) database, together with, for comparative purposes,
those of the current EU. Total cancer mortality for men was 166/100 000 in the EU, but ranged
between 195 (Lithuania) and 269/100 000 (Hungary) in central and eastern European accession
countries. This excess related to most cancer sites, including lung and other tobacco-related neo-
plasms, but also stomach, intestines and liver, and a few neoplasms amenable to treatment, such as
testis, Hodgkin’s disease and leukaemias. Overall cancer mortality for women was 95/100 000 in the
EU, and ranged between 100 and 110/100 000 in several central and eastern European countries, and
up to 120/100 000 in the Czech Republic and 138/100 000 in Hungary. The latter two countries had
a substantial excess in female mortality for lung cancer, but also for several other sites. Furthermore,
for stomach and especially (cervix) uteri, female rates were substantially higher in central and east-
ern European accession countries. Over the last two decades, trends in mortality were systematically
less favourable in accession countries than in the EU. Most of the unfavourable patterns and trends
in cancer mortality in accession countries are due to recognised, and hence potentially avoidable,
causes of cancer, including tobacco, alcohol, dietary habits, pollution and hepatitis B, plus
inadequate screening, diagnosis and treatment. Consequently, the application of available knowledge
on cancer prevention, diagnosis and treatment may substantially reduce the disadvantage now regis-
tered in the cancer mortality of central and eastern European accession countries.
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Introduction
In the 15 member states of the EU in 2003, overall cancer
mortality rates were rising up to 1988, but a reversal of trends
has been observed since, with a fall of  10% in both sexes
between 1988 and 1999, corresponding to the avoidance of
over 90 000 deaths per year compared with the rates in the
late 1980s [1]. The overall favourable pattern of EU cancer
mortality over recent years has been largely driven by the
decline of lung and other tobacco-related cancer mortality in
men [2], but important components of these trends are also
the persistent and substantial fall in gastric cancer [3], the
recent declines in intestinal cancer [4] and of breast cancer in
women [5], together with the long-term falls in cervical cancer
[6], leukaemias [7], Hodgkin’s disease [8], testicular cancer
[9, 10] and other neoplasms that benefit from the advance-
ments in diagnosis and treatment [1]. Over the last few years,
for the first time, some levelling of cancer mortality was
observed also in the Czech Republic, Poland, Hungary and
other central and eastern European countries [1].
In May 2004, 10 additional countries joined the EU, which
include a total of  75 million inhabitants. Of these, eight are
central and eastern European countries (the Czech Republic,
10.3 million; Estonia, 1.4 million; Hungary, 10.2 million; Lat-
via, 2.4 million; Lithuania, 3.5 million; Poland, 38.6 million;
Slovakia, 5.4 million; Slovenia, 7 million), and two are medi-
terranean countries (Cyprus, 0.8 million; Malta, 0.4 million).
Since cancer rates in most central and eastern European
countries are comparatively high, the inclusion of these
countries may unfavourably and appreciably influence future
trends in cancer mortality in the EU [11–13]. It is therefore
important that recent trends in mortality from major cancer
sites in accession countries are considered [1, 14].
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Materials and methods
Official death certification numbers for nine accession countries to the EU
(the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland,
Slovakia and Slovenia) were derived from the World Health Organization
(WHO) database as available on electronic support [15]. Data for Cyprus
were not available. For comparative purposes, data were also abstracted
for the 15 member states of the EU in 2003 (Austria, Belgium, Denmark,
Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, The
Netherlands, Portugal, Spain, Sweden and the UK).
During the calendar period considered (1980–2000), four different revi-
sions of the International Classification of Diseases (ICD) were used.
Classification of cancer deaths was re-coded, for all calendar periods and
countries, according to the Ninth Revision (for further details see [1]). To
improve validity and comparability of data throughout different countries,
we pooled together all intestinal sites including rectum, all uterine cancers
(cervix and endometrium) and all non-Hodgkin’s lymphomas.
Estimates of the resident population, generally based on official cen-
suses, were obtained from the same WHO database. From the matrices of
certified deaths and resident populations, age-specific rates for each 5-year
age group (0–4 to 80–84 and >_85 years) and calendar period were com-
puted. Age-standardised rates per 100 000 population, at all ages and trun-
cated 35–64 years, were computed using the direct method, on the basis
of the world standard population.
Results
Total cancer mortality for men was 165.6/100 000 in the EU.
Malta had a rate of 157/100 000, whereas the eight central and
eastern European accession countries had rates of total cancer
mortality ranging between 194.5 in Lithuania and
269.3/100 000 in Hungary (Table 1). The excess mortality in
accession countries is related to most cancer sites, including
lung (43.7/100 000 for the EU, between 50 and 60/100 000
in most central and eastern European countries, up to
83.1/100 000 in Hungary) and other tobacco-related neoplasms
(oral cavity and pharynx, oesophagus, larynx, pancreas, kid-
ney, bladder), but also stomach, intestines (in most countries),
liver, gallbladder and prostate (in some, but not all accession
countries). There was also an excess mortality for a number of
neoplasms for which there have been advances in treatment,
including testis, Hodgkin’s disease and leukaemias, but not for
non-Hodgkin’s lymphomas.
Overall cancer mortality for women was 94.5/100 000 in
the EU (Table 2). Total cancer mortality rates were similar to
that of the EU in Latvia, Lithuania and Malta, but between
100 and 110/100 000 in several other central and eastern
European countries, up to 119.7 in the Czech Republic and
138.4/100 000 in Hungary. The pattern was more hetero-
geneous than for men across sites. In fact, the Czech Republic
and Hungary had high female mortality rates for lung, but
also for most other cancer sites, whereas other countries
showed a more complex pattern. The only sites showing sys-
tematically higher mortality in central and eastern European
accession countries were stomach, and especially uterus
(mainly cervix).
Overall cancer mortality has declined steadily since the
mid-1980s in males in the EU, but was still increasing up to
the mid-1990s in accession countries, where the most recent
overall rates were about one-third higher than in the EU; the
trend in men aged 35–64 years, however, appears to have
levelled off in the late 1990s (Figure 1). Likewise, total cancer
Table 1. Overall directly age-standardised (world population) death certification rates per 100 000 males from selected cancer or groups of cancer in
European Union (EU) accession countries and in the EU in the year 2000 (unless otherwise indicated in parentheses)
Czech Republic Estonia Hungary Latvia Lithuania Malta
(1999)
Poland Slovakia Slovenia
(1999)
EU
(1999)
Mouth or pharynx 6.8 9.3 21.2 7.9 9.9 7.2 5.9 16.5 9.1 5.6
Oesophagus 4.8 4.4 8.9 5.5 5.7 3.0 4.8 7.5 7.2 5.7
Stomach 12.0 22.5 17.1 20.5 22.0 12.3 16.1 16.0 17.8 9.5
Intestines 35.8 18.1 35.1 17.6 19.0 17.0 19.5 34.3 25.1 18.8
Liver 7.6 6.0 7.7 5.1 3.7 4.9 4.2 6.5 5.8 5.3
Gallbladder 4.2 0.8 3.6 1.0 1.6 0.3 2.0 2.4 3.0 1.4
Pancreas 10.6 9.9 11.2 10.6 9.7 9.1 8.1 9.9 8.1 7.3
Larynx 3.6 3.6 7.6 5.4 5.8 2.7 6.4 6.2 3.7 3.0
Lung 61.6 62.1 83.1 55.5 52.7 39.0 67.9 60.8 54.6 43.7
Prostate 16.8 19.3 17.9 14.6 16.8 14.7 12.6 15.6 17.2 14.6
Testis 0.9 0.5 0.9 0.9 0.6 0.6 0.6 0.6 0.4 0.3
Bladder 7.0 5.7 8.1 8.9 7.6 6.3 8.3 5.4 5.6 6.2
Kidney 10.3 7.5 6.6 7.6 8.3 2.9 6.2 6.5 4.6 4.0
Hodgkin’s disease 0.8 0.3 0.9 0.9 0.8 0.3 0.9 0.9 0.5 0.5
Non-Hodgkin’s
lymphomas
3.6 3.5 3.9 3.7 2.8 6.0 3.1 3.0 2.9 4.4
Leukaemias 7.1 5.3 7.7 6.7 6.4 5.6 5.3 6.0 4.4 5.3
Total cancer mortality 217.0 202.3 269.3 195.9 194.5 157.0 206.4 221.3 198.7 165.6
1426
mortality has been steadily falling in EU women, but not in
accession countries, which now have, as for men, appreciably
higher total mortality rates than the EU (113.4 compared with
94.5/100 000 in the EU at all ages).
Figure 2 gives trends in age-standardised mortality rates for
men (at all ages and at age 35–64 years) for 12 major cancer
sites in accession countries and, for comparative purposes, the
EU between 1980 and 2000. Oral and oesophageal cancer rates
levelled off and then declined in EU men from the late 1980s
onwards, whereas they were still rising appreciably in acces-
sion countries, mostly in middle-aged men. Stomach cancer
rates declined in both the EU and accession countries. The fall
was greater in absolute, but not in relative, terms in accession
countries. Intestinal cancer rates in the early 1980s were lower
in accession countries than in the EU; however, trends tended
to decline in the EU but to increase in accession countries over
the last two decades. Consequently, in the late 1990s, intestinal
cancer rates were much higher in accession countries than in
the EU. Although earlier rising trends appear to have stabilised,
pancreatic cancer mortality was also appreciably higher in
accession countries than in the EU. Laryngeal and lung cancer
rates have been steadily declining in EU men since the early
and mid-1980s, respectively, but have been rising in accession
countries up until the early 1990s. Consequently, laryngeal
Table 2. Overall directly age-standardised (world population) death certification rates per 100 000 females from selected cancer or groups of cancer in
European Union (EU) accession countries and in the EU in the year 2000 (unless otherwise indicated in parentheses)
Czech Republic Estonia Hungary Latvia Lithuania Malta
(1999)
Poland Slovakia Slovenia
(1999)
EU
(1999)
Mouth or pharynx 1.1 1.2 3.1 0.6 1.1 1.6 1.0 1.1 0.6 1.1
Oesophagus 0.6 0.2 1.4 0.3 0.6 0.7 0.8 0.5 1.0 1.3
Stomach 5.7 9.5 7.5 9.3 8.9 3.7 5.8 5.9 7.7 4.4
Intestines 17.7 11.9 20.4 11.5 10.1 12.6 12.1 16.0 13.3 11.7
Liver 3.3 2.5 3.3 1.7 1.4 0.9 2.9 3.0 2.2 1.6
Gallbladder 5.3 1.3 4.7 1.1 2.0 0.3 3.9 4.1 3.2 1.4
Pancreas 6.9 5.1 6.6 5.5 4.4 7.0 5.1 5.4 4.6 4.8
Larynx 0.2 0.2 0.6 0.2 0.1 0.3 0.5 0.3 0.4 0.2
Lung 12.5 7.1 21.8 5.8 4.9 4.9 12.5 8.0 11.2 10.3
Breast 18.7 22.3 23.4 18.0 17.1 23.7 15.0 18.3 21.7 19.0
Uterus, total 9.5 9.5 9.7 10.3 12.8 4.0 10.5 10.8 7.2 4.6
Ovary 7.4 7.9 6.4 6.2 8.9 4.8 6.7 7.0 6.2 5.6
Bladder 1.7 1.3 1.7 1.3 1.1 0.8 1.2 1.0 1.1 1.3
Kidney 4.7 3.0 3.1 2.6 3.5 1.6 2.5 3.2 2.3 1.8
Hodgkin’s disease 0.6 0.3 0.6 0.4 0.6 0.7 0.5 0.7 0.5 0.3
Non-Hodgkin’s
lymphomas
2.5 2.7 2.5 1.6 1.2 3.4 1.6 1.8 2.7 2.8
Leukaemias 4.3 3.6 4.2 3.9 3.7 3.0 3.2 3.4 2.9 3.3
Total cancer mortality 119.7 104.6 138.4 96.7 97.8 93.5 110.5 106.9 107.2 94.5
Figure 1. Trends in directly age-standardised (world population) death certification rates per 100 000 males and females from all cancers in accession
countries and the European Union (EU) from 1980 to 2000. Solid lines, all ages; dashed lines, 35–64 years; +, accession countries; squares, EU. Note:
vertical scales are different for males and females.
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Figure 2. Trends in directly age-standardised (world population) death certification rates per 100 000 males from 12 major cancers in accession countries
and the European Union (EU) from 1980 to 2000. Solid lines, all ages; dashed lines, 35–64 years; +, accession countries; squares, EU.
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Figure 3. Trends in directly age-standardised (world population) death certification rates per 100 000 females from 12 major cancers in accession countries
and the European Union (EU) from 1980 to 2000. Solid lines, all ages; dashed lines, 35–64 years; +, accession countries; squares, EU.
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and lung cancer rates in the late 1990s were substantially higher
in accession countries than in the EU, particularly in the
middle-aged. Prostate cancer rates have been declining in
males in the EU since the early 1990s, but rising in accession
countries, and in the late 1990s rates for men aged 35–64 years
were almost as high as in the EU. Bladder cancer mortality
rates have been declining markedly in the EU, but not in acces-
sion countries. Likewise, mortality trends for testicular cancer,
Hodgkin’s disease and leukaemias were less favourable, and
consequently rates much higher, in the accession countries (as
noted above).
Comparable data for women are given in Figure 3. While
the pattern of trends was similar to that described for men for
major digestive sites, lung cancer rates have been rising in
women in both the EU and accession countries, although to a
greater extent in the latter. Breast and ovarian cancer mortality
have been declining over the last decade in the EU but not in
accession countries, and rates are now comparable in acces-
sion countries and the EU for breast cancer, and higher for
ovarian cancer in accession countries. Mortality from cancer
of the uterus (including mainly cervical cancer) fell both in the
accession countries and in the EU, but in the late 1990s
the rate in accession countries was over twice as high as in
the EU at age 35–64 years.
Discussion
The accession of 10 additional countries to the EU in 2004,
including eight central and eastern European contries with
high mortality from several major cancer sites, will lead to an
increase in overall cancer mortality rates in the EU, as well as
contribute to unfavourable trends over time [11, 12].
The overall analyses by groups of countries, defined essen-
tially on historical and political grounds, are necessarily sim-
plistic in order to convey the message of overall disparity
between EU and accession countries, since important variations
in cancer mortality rates and trends are observed in both groups
of countries, as addressed in detail in a separate paper [1].
It is unlikely that cancer mortality data for the major sites
considered have substantial problems in terms of reliability
and validity that may have falsely given rise to any appreci-
able trends over time in any of the countries considered,
although minor influences due to changes in classification and
coding remain possible [1, 16–18].
Most of the unfavourable patterns and trends in cancer mor-
tality are due to recognised, and hence largely avoidable,
causes of cancer. These include the exceedingly high rates of
lung and other tobacco-related cancers—for Hungarian men
probably the highest ever registered in any developed country
[1, 2, 19]—but also the high rates of gastric and intestinal
cancer, related to poorer and unfavourable dietary patterns
[1, 20, 21].
Alcohol drinking is also responsible for the gross excess
and the consequent unfavourable trends in oral cavity, oeso-
phageal and laryngeal cancers, mostly in Hungary but also in
other central European countries. While the role of type of
alcoholic beverage in cancer risk remains open to discussion,
with a possibly higher risk of fruit-derived ethanol in Hungary
[22–24], the control of alcohol consumption as a whole in
these areas of the continent remains a public health priority
for cancer as well as for several other major diseases [22, 25].
The elevated liver cancer rates seen were largely due to
high hepatitis B and C prevalence [26–29]. Alcohol and
tobacco consumption, however, may also contribute to the
high mortality from liver cancer in Hungary, the Czech
Republic and other countries of central and eastern Europe [30].
Furthermore, there are high mortality rates for neoplasms
related to inadequate screening, diagnosis and treatment,
mainly uterine cervical cancer, with the lack of adoption of
effective screening programs [6, 31], but also breast [5] and
ovarian [32] cancers, as well as testicular cancer [9, 10],
Hodgkin’s disease [8] and leukaemias [7]. Mortality for these
neoplasms in western European countries has been substan-
tially influenced by advancements in integrated chemo- and
radiotherapy approaches [7]. The excess mortality from these
same neoplasms in eastern European accession countries
could therefore be reduced if adequate ressources, training and
logistics to deliver adequate diagnosis and treatment were
implemented [9, 10, 12, 14].
Thus, application of available knowledge on prevention,
diagnosis and treatment of several cancers may substantially
reduce, over the next few years, the major disadvantages now
evident in cancer mortality rates and trends in central and
eastern European accession countries, compared with those in
the 15 EU countries as of 2003 [33].
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